Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I think I'll give up on this!
Re subject title; sorry I don't know how it became "RE: ţ20". Should have been a straight copy and paste of "ţ20".
I guess you mean £20? Cheap, considering we'd have to get to £60+ a share after the 100 fold dilution the very long term shareholders suffered. However, after averaging down and buying the placings I'd be happy with that! Apart from the existing pipeline of potential I wonder how long it will be before a renewed attempt will be made with the FDA for Flutiform to enter the USA market. Given it's success worldwide surely the USA are wondering what they are missing and any potential partner for SKP in this venture would be aware that the success to date diminishes the perceived risk of a successful outcome. I'd like to see an update from the BoD on this subject.
I too recognise the pain of where you are coming from historically and agree with MrBB and, only too well, relate to his account of proceedings. The seas have been very rough and a small miracle has been performed in turning this ship around. Hopefully it will not hit the rocks of an opportunistic bid as it is now picking up a head of steam for a long and fortuitous voyage with a valuable collection of cargo on-board!. I originally believed in the concept but, like many others here, did not foresee the pirating that took place en-route. Patience and averaging down over the long years has served well, particularly along with new management steering a straight course There has been a considerable amount of misfortune for the shareholders over the years and I firmly believe that SKP, and its sp, now has a long way to go and the products to sustain it. The potential is not yet reflected in the sp but this will change as the receipts roll in and further successful product development is realised.
A good RNS update. Just missed out on the $8m Exparel milestone payment in 2015 but the way sales are motoring the triggering $250m sales threshold should be crossed this month to boost 2016 revenues. The question is, will the $500m threshold for the next milestone payment of $32m also be crossed in 2016? A massive boost to revenues if it is.
Thought the following would be of interest. Date: 10:07 am, 26 Aug 2015 / DJ Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com 0907 GMT Analysts have upgraded their full-year sales forecasts for Skyepharma after the specialty pharmaceuticals company said its best-selling inhaler flutiform would exceed expectations. N+1 Singer said it now expects the company to make GBP87.2 million in 2015, compared with its previous estimate of GBP85.9 million. Stifel has raised its full-year revenue forecast to GBP94 million from GBP91.8 million. Skyepharma shares climb 5.6% to 282.25p. (denise.roland@wsj.com; @deniseroland) Contact us in London. +44-20-7842-9464 markettalk@wsj.com 0856 GMT N+1 Singer raises its adjusted pretax profit estimate on Skyepharma by 2% to GBP16.1M for fiscal 2015 and by 6% to GBP30.8M for fiscal 2016 to reflect the better than expected performance of asthma treatment flutiform in the first half. Fiscal 2017 forecasts remain unchanged. Shares +2.6% at 274.25p. (jana.simmons@wsj.com)
You may well be right. Isn't there a rule that enables a maximum holding of 29.9% after which a bid is triggered?
I see that HBM acquired another one million shares on 9th March, taking their holding past another notifiable threshold to 28.28%. Obviously they still think SKP good value and are taking advantage of the current price. I'm surprised the directors have not been taking direct advantage too. Anyone have any thoughts?
Given the growth potential and massive debt reduction of SKP I would think they are very undervalued. I can't guess where it goes from here but look back eleven years or so before all the nasty 100 times dilutions etc., and the share price would have to be around £60 + now compared to the 60 pence + then. I can't in my wildest dreams see that happening but who could have seen £3 + two years ago, from a lowly 40 pence. Perhaps if we small-ish investors have yet more patience we may be fortunate to feel the benefit of long term growth, but watch out for the big boys who may yet spoil our party. I noticed from an RNS last Tuesday that HBM crossed the 27% threshold from 26%, so must think SKP is still good value.